STOCKHOLM — Final results from the phase 3 CLL11 trial confirm the superiority of the newer anti-CD20 monoclonal antibody drug obinutuzumab (Gazyva) compared to the older agent rituximab (Rituxan); both agents are from the same manufacturer, Roche, which sponsored the study.
CLLSA HeathUnlocked post with update on Flair trial - This is a locked post so you will need to be registered with HeathUnlocked to read. If you are interested in CLL then this is a valuable source of reliable information with over 8000 members.
On June 8, 2018, the U.S. Food and Drug Administration (FDA) approved the use of venetoclax (VENCLEXTA) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
This approval is based on data from a clinical trial evaluating venetoclax in combination with rituximab (Rituxan). The trial compared venetoclax plus rituximab with bendamustine plus rituximab in CLL patients who had received at least one prior line of therapy.
The UK CLL Forum is comprised of the most eminent CLL doctors in the UK. They have written to The Times newspaper, following up on the original article which appeared last Saturday. An additional article appeared in the Times today.
Here's the link to the article: thetimes.co.uk/article/nhs-...
And this is the letter:
David Innes, Chair of the CLL Support Association has written to Rt Hon Jeremy Hunt MP to ask him as Secretary of State for Health and Social Care to ensure NHS England follow their legal obligation to fund drugs indications considered by NICE to be cost-effective. A copy of the letter is available below.
NHS England Failing to Fund Ibrutinib in line with NICE Guidance
Many of you will have seen the articles in The Times this weekend which have revealed an issue of immense importance to people living with Chronic Lymphocytic Leukaemia by highlighting NHS England's denial of patient access to ibrutinib despite NICE approval.
What has The Times revealed?
NHS England is currently failing to fund ibrutinib in line with NICE guidance. NICE recommends that ibrutinib alone is recommended within its marketing authorisation as an option for treating CLL in adults: